Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOadjuvant Iparomlimab and Tuvonralimab (QL1706) Plus Chemotherapy in HR+/HER2- Breast Cancer
NCT07396324Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in breast cancer, sponsored by Renji Hospital. Started May 2026; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07396324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396324.